Contact of blood with the surfaces of synthetic materials is associated with spontaneous protein adsorption, initiating platelet aggregation, the coagulation cascade, and the eventual development of a stable clot. Current therapy to inhibit implant-induced thrombosis is life-long administration of systemic anticoagulants. An alternative to the systemic administration of anticoagulant drugs...
As a major natural component of the extracellular matrix (ECM),
hyaluronic acid (HA) is an excellent choice for biomimetic, biocompatible
therapeutic materials. Furthermore, thiol-modified forms of HA are capable of
forming macroporous hydrogels that allow for both controlled cytokine release and
extensive vessel in-growth. It has previously been shown that...
Biocompatible hydrogels composed of covalently crosslinked, chemically modified hyaluronan (HA), gelatin (Gtn), and heparin (Hp) were synthesized for controlled release of human vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF). We hypothesized that inclusion of small quantities of heparin in these gels would result in regulated growth...